Document 0114
 DOCN  M94A0114
 TI    Treatment of oral Candida mucositis infections.
 DT    9412
 AU    Garber GE; Division of Infectious Diseases, Ottawa General Hospital,;
       University of Ottawa, Ontario, Canada.
 SO    Drugs. 1994 May;47(5):734-40. Unique Identifier : AIDSLINE MED/94349844
 AB    Infections due to Candida spp. are increasing in incidence as the number
       of immune compromised patients increases. The common presentation of
       Candida mucositis and oral infections includes atrophic candidiasis,
       angular cheilitis, leukoplakia and oesophagitis. An increasing spectrum
       of antifungal agents, including imidazoles, are available for treatment
       and suppression of this common infection. In chronically
       immune-compromised patients such as those with severe HIV related immune
       deficiency, eradication of the infection may not be possible. This
       requires a stepwise approach to management and may require the use of
       potent, toxic agents such as amphotericin B to suppress the symptoms and
       signs of infection sufficiently to provide the patient with symptomatic
       relief. Resistant organisms are also becoming a greater problem in this
       patient population.
 DE    Adult  Candidiasis, Oral/*DRUG THERAPY  Case Report  Human  Male  Mouth
       Mucosa/DRUG EFFECTS  Risk Factors  Stomatitis/DRUG THERAPY  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).